Lipocine Inc (LPCN) Stock Price, Quote & News

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone...

Industry: Biotechnology

Sector: Healthcare

Phone: 801 994 7383

Fax: 801 994 7388

Website: www.lipocine.com

Address:

675 Arapeen Drive, Suite 202, Salt Lake City, United States

brunoq14 Jan. 17 at 1:00 AM

$LPCN We still have enrollment of 82 (full enrollment) and enrollment of additional participants to go.

0 · Reply

percy4 Jan. 17 at 12:01 AM

$LPCN This would be lovely if the company hadn't done a R/S some time back. If I still had 2000 shares, great. With 200, it has to hit $25 just to get my investment back, no profit. I am sick of R/Ss messing me up with companies I knew would be good. As TLRY just also did for me. And yes, I do average down, So...

1 · Reply

agarfield Jan. 16 at 9:20 PM

$LPCN That 5 year chart makes me depressingly optimistic

0 · Reply

Tothemoonemoji Jan. 16 at 8:41 PM

$LPCN 40k buy at 11.40. Looking good

2 · Reply

DivvyDoo Jan. 16 at 8:05 PM

$LPCN Ratchet up slowly - 200k - 300k volume. Consolidate and build the base for the next powerful move.

0 · Reply

Mr_Greenday Jan. 16 at 3:51 PM

$LPCN started my short position

1 · Reply

DivvyDoo Jan. 16 at 3:38 PM

$LPCN quiet accumulation

0 · Reply

Pedelco Jan. 16 at 12:52 PM

$LPCN I luv my Lipo 🤘

0 · Reply

Ma_pooperz Jan. 15 at 11:59 PM

$LPCN Super red day for market and we still up 2 pts on the day even after going 2-3x. If this was your typical pharma pump and dump we would probably already be back at 6-7 dead cat bounce back to 4.

0 · Reply

az2001 Jan. 15 at 9:07 PM

$LPCN I think something important to note is that biogen own a key competitor to 1154 in Zurzuvae, its very likely in my opinion if we get through topline unscathed that Biogen will come knocking with a buyout. They are a bigger fish and want to retain their foothold on the market, since 1154 has established bioequivalency to Zulresso (the highest efficacy out of any PPD drug on the market) and has a much quicker treatment timeline with 2 days as opposed to Zurzuvae’s 2 weeks, Biogen definitely have the incentive to make an offer in the event of good topline results.

1 · Reply

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Dec 16, 2025, 8:00 AM EST - 4 weeks ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Nov 18, 2025, 8:00 AM EST - 2 months ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 6, 2025, 8:00 AM EST - 2 months ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 4, 2025, 8:00 AM EST - 2 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Sep 30, 2025, 8:00 AM EDT - 3 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 5, 2025, 4:30 PM EDT - 4 months ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 5, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Jun 26, 2025, 8:00 AM EDT - 7 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 23, 2025, 8:00 AM EDT - 7 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 9, 2025, 8:00 AM EDT - 7 months ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

May 22, 2025, 8:00 AM EDT - 8 months ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 14, 2025, 8:00 AM EDT - 8 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 8, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 6, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Mar 26, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 13, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 12, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 1, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 7, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 6, 2024, 8:00 AM EST - 2 years ago

Lipocine to Present at 36th Annual Roth Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Feb 2, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Jan 18, 2024, 8:00 AM EST - 2 years ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Dec 19, 2023, 8:00 AM EST - 2 years ago

Lipocine to Present at Biotech Showcase 2024

Nov 13, 2023, 2:45 PM EST - 2 years ago

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Nov 8, 2023, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Oct 23, 2023, 7:00 PM EDT - 2 years ago

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

brunoq14 Jan. 17 at 1:00 AM

$LPCN We still have enrollment of 82 (full enrollment) and enrollment of additional participants to go.

0 · Reply

percy4 Jan. 17 at 12:01 AM

1 · Reply

agarfield Jan. 16 at 9:20 PM

$LPCN That 5 year chart makes me depressingly optimistic

0 · Reply

Tothemoonemoji Jan. 16 at 8:41 PM

$LPCN 40k buy at 11.40. Looking good

2 · Reply

DivvyDoo Jan. 16 at 8:05 PM

$LPCN Ratchet up slowly - 200k - 300k volume. Consolidate and build the base for the next powerful move.

0 · Reply

Mr_Greenday Jan. 16 at 3:51 PM

$LPCN started my short position

1 · Reply

DivvyDoo Jan. 16 at 3:38 PM

$LPCN quiet accumulation

0 · Reply

Pedelco Jan. 16 at 12:52 PM

$LPCN I luv my Lipo 🤘

0 · Reply

Ma_pooperz Jan. 15 at 11:59 PM

0 · Reply

az2001 Jan. 15 at 9:07 PM

1 · Reply

SadyK189 Jan. 15 at 9:04 PM

Here is my Amazing daily "Stocktwits" report : $ANPA $ROLR $AHMA $LPCN $RCAT ANPA: Price $144. My post last night "Good close of daily candle. Key support at 98 - 109. Next key level to test is 169 - 185" It went till 183 today ROLR Price 17.95. My post last night "Looking good on 4hours chart. Key support at 13.20 - 14. It can test 26 - 27.80 zone again" It hit our desired zone and went till 29.50 AHMA Price 16.20. My post last night "Good close of daily candle. key support at 12.60 - 13.20. Next key level to test is 19.40 - 20.15. Currently at 16.20" It made a nice run to 30.49 today. LPCN: Initially alerted at 5.23. Then posted "12.15 - 12.65 as next key level" last night. It hit our desired zone and went till 12.35 today RCAT Price 10.89. My post was "Looking good on daily chart. Key support at 9.4 - 9.85. Next key level to test is 11.85 - 12.30. Overall it has potential for 15+ though it may take time." It went till 14.64 today. Still looking good on daily chart for 15+

0 · Reply

greetingsoftheday Jan. 15 at 8:35 PM

$LPCN Forgot I still have a chunk of shares from years ago on this ticker. What are ppl who follow this thinking, anyone have price targets, is this a BO candidate/what price?

1 · Reply

az2001 Jan. 15 at 8:33 PM

$LPCN As a 5+ year long like what Im seeing

0 · Reply

oneshotstevie Jan. 15 at 7:08 PM

$LPCN the float is so low, if you sell it might be difficult to get back in at that same price. If a big deal is in the works large institutions will try to get you to sell.

0 · Reply

JackLewisLPCN Jan. 15 at 6:58 PM

$LPCN volume is more important than price right now. Eyeballs are what matters.

0 · Reply

JackLewisLPCN Jan. 15 at 4:03 PM

$LPCN are the diamond hands here yet?

8 · Reply

SadyK189 Jan. 15 at 3:32 PM

$LPCN Initially alerted at 5.23. Kept posting about it regularly. Mentioned 12.15 - 12.65 as next key level in following post last night. It hit our desired zone and at 12.23 right now

1 · Reply

The_Dark_Knight_Rises Jan. 15 at 3:18 PM

$LPCN also look at it from another perspective. The years have been ticking since the setbacks to TLANDO. Patel is not that young anymore. He is in his 60s, perhaps beyond retirement. So this rise may be attributed to some knowledge of discussions that are say, merger, buy out or something else...it is pure conjecture on my part but he isn't exactly a young man and sometimes you have to say that this is a good point to start discussions. Knowing his way of operating, he takes time. So this could be going on for some time now, and the results being good will have weight on price and that promise looks to be coming together with some other firm ..perhaps..I'm reaching but it is plausible at this time.

1 · Reply

The_Dark_Knight_Rises Jan. 15 at 3:00 PM

$LPCN it will gradually head up to big number now. This has to. It is time for it to rise. Give it a few months but I think it has now caught the attention of key people somewhere. Just my intuition

0 · Reply

NothnSpecial Jan. 15 at 12:09 PM

$LPCN I am thinking my PT is $40. I mean I have had these shares for over 5 years. I might as well hold on to them. 🤷‍♂️who knows. Time will tell.

3 · Reply

SadyK189 Jan. 15 at 3:28 AM

$LPCN Initially alerted at 5.23. Currently at 11.20. Still looking good on daily chart. Key support at 9.40 - 9.90. Next key level to test is 12.15 - 12.65.

1 · Reply

chiefcoho Jan. 15 at 2:18 AM

$LPCN Finally the humongous potential is being respected. Let’s squeeze those shorts like a pimple that leaves puss on the mirror!!!

0 · Reply

Market Cap	62.51M
Revenue (ttm)	11.20M
Net Income (ttm)	10,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.09%
Debt to Equity Ratio	0.00

Volume	244,800
Avg Vol	128,646
Day's Range	N/A - N/A
Shares Out	5.55M
Stochastic %K	77%
Beta	0.92
Analysts	Sell
Price Target	$6.88